<DOC>
	<DOCNO>NCT01207063</DOCNO>
	<brief_summary>The investigator group use individualise radiation dose approach dose escalate pre-defined tissue constraint ( see ) . The target dose tumor 69Gy . However , dose reach approximately 30 % patient , even IMRT ( Intensity Modulated Radiotherapy ) technique , MLD ( Mean Lung Dose ) constraint 20Gy reach TTD ( Total Treatment Dose ) 69Gy . In study , investigator adapt treatment perform new ( PET ) -CT day 12 radiotherapy case decrease Planning Target Volume ( PTV ) , dose mey increase .</brief_summary>
	<brief_title>Adaptive Radiotherapy Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Eligible patient receive concurrent chemo-radiotherapy primary tumor initially involve mediastinal lymph node MLD ( Mean Lung Dose ) 20 +/- 1Gy , irrespective lung function . Other dose constraint : spinal cord max : 54Gy , brachial plexus ( Dmax ) :66Gy . In concurrent chemotherapy , radiotherapy deliver follow : 1 . First three week /30 fraction : twice-daily fraction 1.5Gy , 8h 10h interfraction interval , 5 day per week . Total dose : 45Gy/30 fraction . 2 . Thereafter : once-daily fraction 2.0Gy , 5 day per week target dose reach . In sequential radiotherapy alone schedule , twice-daily 1.8Gy interfraction interval least 8h deliver . The radiation dose specify accord ICRU 50 . Lung density correction apply , well standard QA procedure . Technical requirement standard practice MAASTRO clinic . Chemotherapy schedule allow : 1 . 1-2 cycle induction chemotherapy : third generation schedule allow . The type register . 2 . Concurrent part : ( day 1=first day radiotherapy ) 1. cisplatin-vinorelbine 2. cisplatin-docetaxel 3. cisplatin-etoposide 4. cisplatin-pemetrexed non-squamous histology Q3 week ; 3 cycle When calculate creatinin clearance le 60 ml/min , cisplatin may substitute carboplatin . In case TTD ( Total Treatment Dose ) =69Gy reach limit MLD , FDG-PET-CT perform day 12 radiotherapy . GTV 's ( Gross Tmor Volume ) , CTV 's ( Clinical Target Volume ) PTV 's ( Planning Target Volume ) delineate new plan calculate . The endpoint proportion patient receive 69Gy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological proven NSCLC UICC stage IIII , solitary metastasis ( &lt; 6 ) , amendable radical local treatment Performance status 02 IMRT technique Not NSCLC mixed NSCLC histology ( e.g . small cell carcinoma ) Stage IV , except solitary ( &lt; 6 ) metastasis Performance status 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Stage II-III non-small cell lung cancer</keyword>
</DOC>